This article is more than 5 years old. Information may no longer be current.
Management changes at Santen Ltd. herald an increased focus on US market
Click Here to Manage Email Alerts
OSAKA, Japan — Santen Ltd. announced changes in its management structure intended to support an increased focus on the U.S. market, according to a press release from the company.
Adrienne L. Graves, PhD, has resigned as president and CEO of wholly owned U.S. subsidiary Santen Inc. She will continue to serve as an adviser to senior Santen management.
Toshiaki Nishihata, PhD, will assume the title of CEO of Santen Inc., effective April 1. In addition, he will continue serving as a member of the board, senior corporate officer and head of the research and development division.
Akihiro Tsujimura will assume the post of chief operating officer of Santen Inc. He has previously led the business development department.
"We are focused on building a robust pipeline, particularly in support of an increased presence in the U.S. market, and we are aggressively expanding our clinical and business development efforts to support the company's international expansion," Akira Kurokawa, president and CEO of Santen Ltd., said in the release. "This change in management structure will increase the communication and corporate focus on the U.S. market."
Dr. Graves will continue to serve as a strategic consultant and adviser to the company's senior management and participate on several industry boards. She was responsible for obtaining three new drug approvals and serves on the boards of several ophthalmic organizations.
In addition, Dr. Graves and Marguerite B. McDonald, MD, co-founded Ophthalmic Women Leaders.
Follow OSNSuperSite.com
on Twitter.